Studie Pasritamig versus placebo v pozdní linii metastatická kastrace rezistentní rakovina prostaty (MCRPC) (KLK2-comPAS)
Randomizovaná, dvojitě slepá, placebem kontrolovaná studie Pasritamig (JNJ-78278343), přesměrovací činidlo T buněk zaměřené na člověka Kallikrein 2, + Nejlepší podpůrná péče pro metastatickou péči o rakovinu prostaty T buněk zaměřujícím
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Study Contact
- Telefonní číslo: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studijní místa
-
-
-
Heidelberg, Austrálie, 3084
- Nábor
- Warringal Private Hospital
-
Kurralta Park, Austrálie, 5037
- Nábor
- ICON Cancer Care
-
Melbourne, Austrálie, 3000
- Nábor
- Peter MacCallum Cancer Centre
-
Murdoch, Austrálie, 6150
- Nábor
- Fiona Stanley Hospital
-
Woolloongabba, Austrálie, 4102
- Nábor
- Princess Alexandra Hospital
-
-
-
-
-
Bruges, Belgie, 8000
- Nábor
- AZ Sint-Jan
-
Brussels, Belgie, 1200
- Nábor
- Cliniques Universitaires Saint Luc
-
Ghent, Belgie, 9000
- Nábor
- Ghent University Hospital
-
Ghent, Belgie, 9000
- Nábor
- AZ Maria Middelares
-
Kortrijk, Belgie, 8500
- Nábor
- Az Groeninge
-
La Louvière, Belgie, 7100
- Nábor
- Chu Helora Hospital La Louviere Site Jolimont
-
Liège, Belgie, 4000
- Nábor
- CHC MontLegia
-
Ottignies, Belgie, 1340
- Nábor
- Clinique Saint Pierre
-
Wilrijk, Belgie, 2610
- Nábor
- ZAS Augustinus
-
-
-
-
-
Florianópolis, Brazílie, 88020 210
- Nábor
- Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
-
Joinville, Brazílie, 89201 260
- Nábor
- Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
-
Natal, Brazílie, 59062 000
- Nábor
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brazílie, 90035-001
- Nábor
- Hospital Moinhos de Vento
-
São Paulo, Brazílie, 01509 900
- Nábor
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
-
-
-
-
Bordeaux, Francie, 33000
- Nábor
- Institut Bergonie
-
Brest, Francie, 29200
- Nábor
- CHRU Brest - Hopital Morvan
-
Dijon, Francie, 21000
- Nábor
- Centre Georges Francois Leclerc
-
Lille, Francie, 59000
- Nábor
- Centre Oscar Lambret
-
Lyon, Francie, 69008
- Nábor
- Centre Leon Berard
-
Paris, Francie, 75014
- Nábor
- Hopital Saint Joseph
-
Pierre-Bénite, Francie, 69495
- Nábor
- CHU Lyon Sud
-
Saint-Herblain, Francie, 44805
- Nábor
- I.C.O. Rene Gauducheau
-
Strasbourg, Francie, 672098
- Nábor
- Hopitaux universitaires de Strasbourg
-
Vandœuvre-lès-Nancy, Francie, 54519
- Nábor
- Institut de Cancerologie de Lorraine
-
Villejuif, Francie, 94800
- Nábor
- Gustave Roussy
-
-
-
-
-
Delft, Holandsko, 2625 AD
- Nábor
- Reinier de Graaf Gasthuis
-
Groningen, Holandsko, 9728NT
- Dokončeno
- Martini Ziekenhuis
-
Hilversum, Holandsko, 1212 VG
- Nábor
- Tergooi
-
Hoofddorp, Holandsko, 2134 TM
- Nábor
- Spaarne Gasthuis
-
Maastricht, Holandsko, 6229 HX
- Nábor
- Maastricht UMC
-
Nijmegen, Holandsko, 6532 SZ
- Nábor
- Canisius-Wilhelmina ZH
-
Rotterdam, Holandsko, 3015 GD
- Nábor
- Erasmus MC
-
Zwolle, Holandsko, 8025 AB
- Nábor
- Isala Kliniek
-
-
-
-
-
Foggia, Itálie, 71122
- Nábor
- Ospedali Riuniti Foggia
-
Milan, Itálie, 20133
- Nábor
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Naples, Itálie, 80131
- Nábor
- Azienda Ospedaliera Universitaria Federico II
-
Padova, Itálie, 35128
- Nábor
- IOV IRCCS Padova
-
Palermo, Itálie, 90127
- Nábor
- Azienda Di Rilievo Nazionale E Di Alta Specializzazione
-
Roma, Itálie, 00168
- Nábor
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Itálie, 20089
- Nábor
- Istituto Clinico Humanitas
-
Torino, Itálie, 10126
- Nábor
- A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
-
-
-
-
-
Bunkyō City, Japonsko, 113 8519
- Nábor
- Institute of Science Tokyo Hospital
-
Fukuoka, Japonsko, 812 8582
- Nábor
- Kyushu University Hospital
-
Gifu, Japonsko, 501-1194
- Nábor
- Gifu University Hospital
-
Hidaka, Japonsko, 350 1298
- Nábor
- Saitama Medical University International Medical Center
-
Kanazawa, Japonsko, 920 8641
- Nábor
- Kanazawa University Hospital
-
Kashiwa, Japonsko, 277 8577
- Nábor
- National Cancer Center Hospital East
-
Kobe, Japonsko, 650 0017
- Nábor
- Kobe University Hospital
-
Matsuyama, Japonsko, 791-0280
- Nábor
- National Hospital Organization Shikoku Cancer Center
-
Meguro Ku, Japonsko, 152 8902
- Nábor
- National Hospital Organization Tokyo Medical Center
-
Sakura, Japonsko, 285-8741
- Nábor
- Toho University Sakura Medical Center
-
Sapporo, Japonsko, 060 8648
- Nábor
- Hokkaido University Hospital
-
Yokohama, Japonsko, 232 0024
- Nábor
- Yokohama City University Medical Center
-
Yokohama, Japonsko, 236 0004
- Nábor
- Yokohama City University Hospital
-
Yokosuka, Japonsko, 238 8558
- Nábor
- Yokosuka Kyosai Hospital
-
-
-
-
-
Daejeon, Jižní Korea, 35015
- Nábor
- Chungnam National University Hospital
-
Goyang-si, Jižní Korea, 10408
- Nábor
- National Cancer Center
-
Hwasungun, Jižní Korea, 58128
- Nábor
- Chonnam National University Hwasun Hospital
-
Seoul, Jižní Korea, 05505
- Nábor
- Asan Medical Center
-
Seoul, Jižní Korea, 06351
- Nábor
- Samsung Medical Center
-
Seoul, Jižní Korea, 03722
- Nábor
- Severance Hospital Yonsei University Health System
-
Seoul, Jižní Korea, 06591
- Nábor
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5G2
- Nábor
- Arthur J E Child Comprehensive Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- Nábor
- BC Cancer Vancouver
-
-
Ontario
-
Oshawa, Ontario, Kanada, L1G2B9
- Nábor
- Lakeridge Health
-
Toronto, Ontario, Kanada, M4N 3M5
- Nábor
- Sunnybrook Health Sciences Center
-
Toronto, Ontario, Kanada, M5G 2C1
- Nábor
- Princess Margaret Hospital
-
-
Quebec
-
Québec, Quebec, Kanada, G1J 1Z4
- Nábor
- CHU de Quebec Universite Laval
-
-
-
-
-
Braunschweig, Německo, 38126 DE
- Nábor
- Staedtisches Klinikum Braunschweig
-
Duisburg, Německo, 47169
- Nábor
- Urologicum Duisburg
-
Düsseldorf, Německo, 40225
- Nábor
- Universitaetsklinikum Duesseldorf
-
Essen, Německo, 45147
- Nábor
- Universitaetsklinikum Essen
-
Frankfurt am Main, Německo, 60488
- Nábor
- Krankenhaus NorthWest
-
Hamburg, Německo, 20246
- Nábor
- Martini-Klinik am UKE GmbH
-
Heidelberg, Německo, 69120
- Nábor
- Universitaetsklinikum Heidelberg Nationales Centrum fuer Tumorerkrankungen
-
München, Německo, 81675
- Nábor
- Klinikum rechts der Isar der TU Muenchen
-
Münster, Německo, 48149
- Nábor
- Universitaetsklinikum Muenster
-
Nuremberg, Německo, 90419
- Nábor
- Klinikum Nuernberg Nord
-
Nürtingen, Německo, 72622
- Nábor
- Studienpraxis Urologie Nurtingen
-
-
-
-
-
Bialystok, Polsko, 15 276
- Nábor
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Polsko, 85 048
- Nábor
- IN VIVO Sp. z o.o
-
Koszalin, Polsko, 75-581
- Nábor
- Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie
-
Warsaw, Polsko, 02 781
- Nábor
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Warsaw, Polsko, 04 073
- Nábor
- Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O
-
-
-
-
-
Rio Piedras, Portoriko, 00935
- Nábor
- Pan American Center for Oncology Trials LLC
-
San Juan, Portoriko, 00917
- Nábor
- Puerto Rico Medical Research Center
-
-
-
-
-
Birmingham, Spojené království, B15 2TH
- Nábor
- University Hospitals Birmingham NHS Foundation Trust
-
London, Spojené království, WC1E 6BT
- Nábor
- University College London Hospitals
-
Manchester, Spojené království, M20 4BX
- Nábor
- The Christie NHS Foundation Trust Christie Hospital
-
Sutton, Spojené království, SM2 5PT
- Nábor
- Royal Marsden Hospital (Sutton)
-
-
-
-
California
-
La Jolla, California, Spojené státy, 92093
- Nábor
- University of California at San Diego
-
Los Angeles, California, Spojené státy, 90048
- Nábor
- Cedars Sinai Medical Center
-
Los Angeles, California, Spojené státy, 90095
- Nábor
- Ronald Reagan UCLA Medical Center
-
San Francisco, California, Spojené státy, 94121
- Nábor
- San Francisco VA Medical Center
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Nábor
- University of Colorado Cancer Center
-
Aurora, Colorado, Spojené státy, 80012
- Nábor
- Rocky Mountain Cancer Centers
-
Lakewood, Colorado, Spojené státy, 80228
- Nábor
- Colorado Clinical Research
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06102
- Nábor
- Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20016
- Nábor
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
-
-
Florida
-
Bay Pines, Florida, Spojené státy, 33744
- Nábor
- Bay Pines VA Healthcare System
-
Fort Myers, Florida, Spojené státy, 33901
- Nábor
- Florida Cancer Specialists & Research Institute
-
Tampa, Florida, Spojené státy, 33612
- Nábor
- Moffitt Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Spojené státy, 52242
- Nábor
- University of Iowa Hospital and Clinics
-
Waukee, Iowa, Spojené státy, 50263
- Nábor
- Mission Cancer Blood
-
-
Louisiana
-
Metairie, Louisiana, Spojené státy, 70006
- Nábor
- East Jefferson General Hospital
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Nábor
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Nábor
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- Nábor
- University of Michigan Health System
-
Detroit, Michigan, Spojené státy, 48202
- Nábor
- Henry Ford Cancer Detroit
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55455
- Nábor
- University Of Minnesota Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68130
- Dokončeno
- XCancer Omaha / Urology Cancer Center
-
-
New York
-
Brooklyn, New York, Spojené státy, 11220
- Nábor
- NYU Langone Hospitals
-
Mineola, New York, Spojené státy, 11501
- Nábor
- NYU Langone Hospital Long Island
-
New York, New York, Spojené státy, 10032
- Nábor
- Columbia University Medical Center
-
New York, New York, Spojené státy, 10016
- Nábor
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28204
- Nábor
- Levine Cancer Institute
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Nábor
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45219
- Nábor
- University of Cincinnati
-
Cleveland, Ohio, Spojené státy, 44106
- Nábor
- University Hospital of Cleveland
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Nábor
- VA Portland Health Care System
-
Portland, Oregon, Spojené státy, 97227
- Dokončeno
- Compass Oncology
-
Portland, Oregon, Spojené státy, 97239
- Nábor
- Oregon Health And Science University
-
Springfield, Oregon, Spojené státy, 97477
- Nábor
- Oregon Urology Institute
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Spojené státy, 19004
- Nábor
- MidLantic Urology
-
Lancaster, Pennsylvania, Spojené státy, 17601
- Nábor
- Keystone Urology Specialists
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Nábor
- Penn Medicine Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Spojené státy, 15232
- Nábor
- UPMC Cancer Centers
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29401
- Nábor
- Ralph H Johnson Veterans Hospital
-
Greer, South Carolina, Spojené státy, 29650
- Nábor
- Gibbs Cancer Center and Research Institute Pelham
-
Myrtle Beach, South Carolina, Spojené státy, 29572
- Nábor
- Carolina Urologic Research Center
-
Spartanburg, South Carolina, Spojené státy, 29303
- Nábor
- Gibbs Cancer Center
-
-
Tennessee
-
Chattanooga, Tennessee, Spojené státy, 37404
- Nábor
- Tennessee Oncology - Chattanooga
-
Nashville, Tennessee, Spojené státy, 37203
- Nábor
- Tennessee Oncology Nashville
-
-
Texas
-
Dallas, Texas, Spojené státy, 75390
- Nábor
- UT Southwestern Medical Center
-
Dallas, Texas, Spojené státy, 75231
- Dokončeno
- Urology Clinics of North Texas
-
Houston, Texas, Spojené státy, 77030
- Nábor
- MD Anderson Cancer Center
-
Houston, Texas, Spojené státy, 77030
- Nábor
- Michael E DeBakey VA Medical Center
-
Wichita Falls, Texas, Spojené státy, 76310
- Nábor
- Texas Oncology West Texas
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84106
- Nábor
- Utah Cancer Specialists
-
-
Virginia
-
Fairfax, Virginia, Spojené státy, 22031
- Nábor
- Virginia Cancer Specialists
-
Norfolk, Virginia, Spojené státy, 23502
- Nábor
- Virginia Oncology Associates
-
Roanoke, Virginia, Spojené státy, 24014
- Nábor
- Blue Ridge Cancer Care
-
-
Washington
-
Seattle, Washington, Spojené státy, 98195
- Nábor
- University of Washington
-
Seattle, Washington, Spojené státy, 98109
- Nábor
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Spojené státy, 98108
- Nábor
- VA Puget Sound Healthcare System
-
-
-
-
-
Kaohsiung City, Tchaj-wan, 833
- Nábor
- Chang Gung Memorial Hospital
-
Taichung, Tchaj-wan, 40705
- Nábor
- Taichung Veterans General Hospital
-
Taichung, Tchaj-wan, 435
- Nábor
- Tungs' Taichung MetroHarbor Hospital
-
Taipei, Tchaj-wan, 100
- Nábor
- National Taiwan University Hospital
-
Taipei, Tchaj-wan, 112
- Nábor
- Taipei Veterans General Hospital
-
Taoyuan, Tchaj-wan, 333
- Nábor
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Beijing, Čína, 100034
- Nábor
- Peking University First Hospital
-
Changchun, Čína, 130021
- Nábor
- The First Bethune Hospital of Jilin University
-
Chengdu, Čína, 610041
- Nábor
- West China Hospital of Sichuan University
-
Chengdu, Čína, 500643
- Nábor
- The Third People's Hospital of Chengdu
-
Chongqing, Čína, 400030
- Nábor
- Chongqing University Cancer Hospital
-
Guangzhou, Čína, 510060
- Nábor
- Sun Yat Sen University Cancer Center
-
Nanjing, Čína, 210008
- Nábor
- Nanjing Drum Tower Hospital
-
Nanning, Čína, 530021
- Nábor
- The First Affiliated Hospital of Guangxi Medical University
-
Nantong, Čína, 226300
- Nábor
- Nantong Tumor Hospital
-
Ningbo, Čína, 315010
- Nábor
- The First Affiliated Hospital of Ningbo University
-
Shanghai, Čína, 200032
- Nábor
- Fudan University Shanghai Cancer Center
-
Tianjin, Čína, 300211
- Nábor
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Čína, 325000
- Nábor
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Čína, 430071
- Nábor
- Zhongnan Hospital Wu Han University
-
Xi'an, Čína, 710061
- Nábor
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Barcelona, Španělsko, 08035
- Nábor
- Hosp Univ Vall D Hebron
-
Jerez de la Frontera, Španělsko, 11407
- Dokončeno
- Hosp. de Jerez de La Frontera
-
Madrid, Španělsko, 28034
- Nábor
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Španělsko, 28041
- Nábor
- Hosp. Univ. 12 de Octubre
-
Málaga, Španělsko, 29010
- Nábor
- Hosp Virgen de La Victoria
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria
- Histologically confirmed adenocarcinoma of the prostate
- Metastatic castration-resistant prostate cancer (mCRPC): Disease that is metastatic either to bone, any lymph node, or both without clear evidence of other metastatic sites at the time of screening by conventional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) (chest, abdomen, and pelvis) and 99m^Tc bone scan. Visceral disease is not allowed
- PSA greater than or equal to (≥) 2 nanogram per milliliter (ng/mL) at screening
- In the opinion of the investigator, the next best treatment option is a clinical trial
- Participants are required to have had all life-prolonging therapies for which they are clinically eligible in the opinion of the investigator and to which they have access. Prior therapies could have been given in any disease setting (not limited to mCRPC). In particular, prior treatment specifications include receipt of the following:
Androgen-receptor pathway inhibitor (ARPI): Must have progressed on at least 1 ARPI and unlikely to benefit from retreatment with another ARPI
Taxanes: Required to have received at least 2 previous taxane-based regimens. If a participant has received only 1 taxane regimen, the participant is eligible if:
- Cabazitaxel is not available
- The participant's physician deems the participant unsuitable to receive a second taxane regimen due to toxicity risk or prior intolerance Note: a taxane-based regimen consists of at least 2 cycles of a taxane (either as a single agent or in combination with other therapies) administered within the same 2-month period
Radioligand therapy: Required to have been previously treated with at least 1 dose of Prostate-specific membrane antigen (PSMA)-targeted lutetium radioligand therapy (eg, lutetium Lu-177 vipivotide tetraxetan), unless one of the following applies:
- PSMA-targeted lutetium radioligand therapy is unavailable, not accessible, or not clinically indicated.
- The participant's physician deems the participant unsuitable to receive PSMA-targeted lutetium radioligand therapy.
Polyadenosine diphosphate-ribose polymerase inhibitors (PARPi): Required to have been previously treated with PARPi, if the participant has a known germline or somatic BRCA mutation and treatment is available
- Prior orchiectomy or medical castration (receiving ongoing ADT with a GnRH analog [agonist or antagonist]) prior to the first dose of study treatment and must continue this therapy throughout the treatment phase
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Participants are eligible if they have the following values:
A) eGFR ≥ 40 milliliters per minute (mL/min) B) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) less than or equal to (≤) 3 times the Upper Limit of Normal (ULN) C) Total bilirubin <1.5 times ULN D) Absolute neutrophil count (ANC) ≥ 1.0x10^9/per liter (L) E) Hemoglobin ≥ 8.0 grams per deciliter (g/dL) F) Platelet count ≥ 75x10^9/L
Exclusion Criteria
- Venous thromboembolic events within 1 month prior to the first dose of study treatment; uncomplicated (Grade ≤ 2) deep vein thrombosis is not exclusionary
- Active autoimmune disease within the past 12 months that requires systemic immunosuppressive medications (eg, chronic corticosteroid, methotrexate, or tacrolimus)
- Participants with Grade 1 or higher fever (≥38ºC) or active infection requiring systemic treatment within 7 days prior to randomization are ineligible. Participants must be afebrile (<38ºC) at the time of study treatment dosing unless approved by medical monitor
- Clinically significant pulmonary compromise, particularly a requirement for supplemental oxygen use (>2 liters per minute (L/min) by nasal cannula) to maintain adequate oxygenation
- Prior or concurrent second malignancy (other than the disease under study) for which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Any of the following within 6 months prior to first dose of study treatment:
A) Myocardial infarction B) Severe or unstable angina C) Clinically significant ventricular arrhythmias D) Congestive heart failure (New York Heart Association class II to IV) E) Transient ischemic attack F) Cerebrovascular accident
- Prior treatment with any CD3-directed therapy
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Part 1: Pasritamig+Best Supportive Care (BSC)
Participants in Part 1 will receive 2 step-up doses of pasritamig intravenously (IV) followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Ostatní jména:
BSC will be administered at the discretion of the treating physician. |
|
Komparátor placeba: Part 1: Placebo+BSC
Participants in Part 1 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
BSC will be administered at the discretion of the treating physician. Placebo will be administrated through IV infusion. |
|
Experimentální: Part 2: Pasritamig+BSC
Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Ostatní jména:
BSC will be administered at the discretion of the treating physician. |
|
Experimentální: Part 2: Pasritamig+JNJ-87189401+BSC
Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. JNJ-87189401 will be administered with the first target dose of pasritamig. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Ostatní jména:
BSC will be administered at the discretion of the treating physician. JNJ-87189401 will be administered. |
|
Komparátor placeba: Part 2: Placebo +BSC
Participants in Part 2 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
BSC will be administered at the discretion of the treating physician. Placebo will be administrated through IV infusion. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall Survival (OS)
Časové okno: Up to 2 years and 8 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to 2 years and 8 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Radiographic Progression-free Survival (rPFS)
Časové okno: Up to 2 years and 8 months
|
rPFS assessed by investigator defined as the time from the date of randomization until the date of radiographic disease progression (based on response evaluation criteria in solid tumors [RECIST] version (v) 1.1 and prostate cancer working group 3 [PCWG3] criteria) or death, whichever comes first. |
Up to 2 years and 8 months
|
|
Time to Symptomatic Progression
Časové okno: Up to 2 years and 8 months
|
Time to symptomatic progression is defined as time from the date of randomization to the date of any of the following (whichever occurs first): (a) the use of external beam radiation therapy to relieve cancer-related symptoms; (b) the need for tumor-related orthopedic surgical intervention; (c) other cancer-related procedures; (d) cancer-related morbid events; (e) initiation of a new systemic anti-cancer therapy because of cancer symptoms. |
Up to 2 years and 8 months
|
|
Time to Skeletal-Related Event
Časové okno: Up to 2 years and 8 months
|
Time to skeletal-related event is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): (a) the use of external beam radiation for skeletal or pelvic symptoms; b) the need for tumor-related orthopedic surgical intervention; (c) the occurrence of new bone fractures (cancer-related); (d) the occurrence of tumor-related spinal cord compression. |
Up to 2 years and 8 months
|
|
Progression-Free Survival (PFS)
Časové okno: Up to 2 years and 8 months
|
PFS is defined as the date of randomization to the date of first evidence of radiographic progression, clinical progression, or death from any cause, whichever occurs first. |
Up to 2 years and 8 months
|
|
Time to Prostate Specific Antigen (PSA) Progression
Časové okno: Up to 2 years and 8 months
|
Time to PSA progression, defined as the time from randomization to the first date of documented PSA progression per PCWG3 criteria. PSA progression is defined as: after a decline from baseline, PSA increases >= 25 percentage (%) and >= 2 nanograms per milliliter (ng/mL) above the nadir, confirmed by a second value >= 3 weeks later (that is, a confirmed rising trend), or If there is no decline from baseline, PSA increases >= 25 % and >= 2 ng/mL from baseline after 12 weeks. |
Up to 2 years and 8 months
|
|
Time to Pain Progression (TTPP) as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) Item 3 Worst Pain in 24 Hours
Časové okno: Up to 2 years and 8 months
|
TTPP is defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression is defined as an increase of at least 2 points from baseline in the BPI-SF worst pain intensity (item 3) observed at 2 consecutive evaluations >= 3 weeks apart. BPI-SF is an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score range from 0 to 10 with 0 representing "no pain" and 10 representing" pain as bad as you can imagine". |
Up to 2 years and 8 months
|
|
Time to Deterioration in Fatigue as Assessed by the European Organisation For Research And Treatment of Cancer Quality of Life Questionnaire-Core-30 (EORTC QLQ-C30) Fatigue Scale Score
Časové okno: Up to 2 years and 8 months
|
Time to deterioration is defined as the time from randomization to the date of the first observation of deterioration in Fatigue. Deterioration in Fatigue is defined as an increase of 10 points on the EORTC QLQ-C30 FA scale observed at 2 consecutive evaluations >= 3 weeks apart. The EORTC QLQ-C30 is a widely used tool for assessing the quality of life of cancer patients in clinical trials. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". Each subscale of the EORTC QLQ-C30 is scored on a range from 0 to 100. Higher scores indicate worse symptoms or problems. |
Up to 2 years and 8 months
|
|
Number of Participants with Adverse Events (AEs)
Časové okno: Up to 2 years and 8 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years and 8 months
|
|
Number of Participants with Abnormalities in Clinical Laboratory Assessments
Časové okno: Up to 2 years and 8 months
|
Participants with abnormalities in clinical laboratory parameters (hematology, clinical chemistry etc.) will be assessed. |
Up to 2 years and 8 months
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 78278343PCR3001
- 2025-520927-26-00 (Identifikátor registru: EUCT number)
- 2025 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .